AlphaSIP
AlphaSIP is a company specializing in nanotechnology and medical diagnostics. They have invested over 22 million euros in R&D since 2007, with a significant portion allocated to molecular diagnostics and PCR systems. Their core focus is developing universal systems that can be used by non-experts, offering multi-testing capabilities without requiring a clean room or viral containment hood. They have developed products like DrugSIP, a rapid drug test, and CoronaSIP UltraFAST PCR, a molecular diagnostic test delivering results in 19 minutes. AlphaSIP's platform, MedBOX, integrates extraction, thermocycling, and computing, aiming to save costs on personnel, space, and energy. They are also involved in developing smart catheters with flexible electronics and microfluidics, and are collaborating with Philips on AI-driven synthetic imaging.
AlphaSIP
AlphaSIP is a company specializing in nanotechnology and medical diagnostics. They have invested over 22 million euros in R&D since 2007, with a significant portion allocated to molecular diagnostics and PCR systems. Their core focus is developing universal systems that can be used by non-experts, offering multi-testing capabilities without requiring a clean room or viral containment hood. They have developed products like DrugSIP, a rapid drug test, and CoronaSIP UltraFAST PCR, a molecular diagnostic test delivering results in 19 minutes. AlphaSIP's platform, MedBOX, integrates extraction, thermocycling, and computing, aiming to save costs on personnel, space, and energy. They are also involved in developing smart catheters with flexible electronics and microfluidics, and are collaborating with Philips on AI-driven synthetic imaging.